Please input keywords

YH005 is an anti-Claudin 18.2 antibody generated using our Claudin 18.2 knock-out mice. We have out-licensed YH005 to RemeGen for the development RC118, a potentially first-in-class ADC for the treatment of solid tumors. RC118 has obtained TGA approval for clinical trials in Australia and is currently under IND application process in China.
naver-site-verification: naver8a6b0412e3d2d9dd38f1684b831435ac.html